



Palex, the leading distributor of high value-added MedTech equipment and solutions, announces the completion of the acquisition Wacrees, S.A., contributing to its diversification and growth plan.

- **This new acquisition is a clear commitment to innovation and minimally invasive procedures.**
- **With the backing of Fremman Capital, Palex Medical is pursuing its growth and diversification plan, previously supported by Ergon Capital and Corpfin Capital, since 2016.**

Grupo Palex has recently acquired Wacrees, a company founded in 1991 and engaged in researching the best solutions for vascular and interventional radiology treatments, in collaboration with world-class partners. With this new acquisition, Palex expands its offer caring for patients undergoing vascular operations, strengthens its growth and diversification plan that got underway in 2016, and reinforces its commitment to innovation and minimally invasive procedures.

The incorporation of Wacrees, which, as well as the recent acquisitions of Comercial Rafer and the proton therapy branch of Bioterra, will expand the number of specialties for which Palex offers solutions and consolidate its leading position in the Spanish market.

Wacrees' high level of commitment to its customers has led to in long-term commercial agreements with its international partners.

Palex and Wacrees share the goal of offering maximum innovation to the different medical specialties and this acquisition strengthens Palex's commitment to offer minimally invasive solutions and procedures.

Xavier Carbonell, CEO of the Palex Group, points out: *"Acquiring Wacrees as well as our extensive knowledge of the market in Spain and Portugal means we will have access to new innovative solutions that will strengthen our leadership in the industry and boost our capacity to successfully meet the challenges that healthcare professionals and patients' quality of life demand"*.